Recce Pharmaceuticals Ltd

Founded by Dr. Graham Melrose in 2008, Recce Pharmaceuticals (ASX: RCE) emerged from his extensive experience at Johnson & Johnson, leverages Dr. Melrose’s pioneering research to create new classes of synthetic anti-infectives. It was named Recce (pronounced ‘Wreck-key’) because Recce is the standard military shortening of the word ‘reconnaissance’. It intended to have a military-like impact on superbugs. The company was listed in 2016, and over the years, Recce has advanced its drug candidates, through the clinic. R327 is the candidate that is most advanced. The drug, which can be administered topically or intravenously, has a Unique Mechanism of Action, working fast and continuing to work just as effectively with repeated use. Endurance is something existing antimicrobal solutions tend to stumble at, especially when bacteria mutates. Mutation is where the sequence of bacteria alters and one of the consequential effects can be resistance to antibiotics. As of February 2026, the company has several clinical trials underway but the most important is a Phase 3 trial underway in Indonesia for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). ABSSSI is a term including several conditions including diabetic foot infections (DFI) and postoperative wound infections. This study, which is one of the largest studies in the world of its kind, followed successful Phase 2 results in 2024. The other key program is advancing R327 against burn wound infections. It is in a collaboration with the US Army to evaluate R327G in a pre-clinical model, specifically to assess its ability to fight pathogens that can occur with burn wound infections.